Medpace is a global, full-service contract research organization (CRO) specializing in the design and management of clinical trials for the pharmaceutical, biotechnology, and medical device industries. Founded in 1992 and headquartered in Cincinnati, Ohio, Medpace partners with sponsors to accelerate the development of safe and effective medical therapies. The company is recognized for its scientifically-driven approach, therapeutic expertise, and integrated services, which include clinical trial management, regulatory affairs, data management, and laboratory services. With over 5,800 employees worldwide as of 2024, Medpace has built a reputation for high-quality execution and personalized service, supporting clients from early-phase development through post-marketing studies. Medpace is publicly traded on the NASDAQ (ticker: MEDP) and has consistently reported strong financial performance and growth. In recent news, Medpace has expanded its global footprint with new facilities and investments in advanced clinical technologies, further solidifying its position as a leading CRO in the life sciences sector.